ATSP1是我们借助多肽组学获得的一条腹部脂肪组织分泌的生物活性肽，在正常排卵妇女组及PCOS减重后恢复排卵组中表达，具有物种间高度保守且稳定性高的特征，既往未有功能报道。前期体内体外实验初步证实ATSP1有促进PCOS患者颗粒细胞增殖、改善PCOS模型大鼠排卵的作用，Pull-down实验揭示FOXO1可能是其发挥作用的关键分子，FOXO1是一个定位在卵巢颗粒细胞中的转录因子，在调控颗粒细胞功能及卵泡凋亡中发挥重要的调控角色。据此我们提出“ATSP1通过抑制FOXO1的功能调控PCOS中颗粒细胞功能”的假说。本研究拟通过体外和体内两方面系统评估多肽ATSP1的作用。以FOXO1为机制线索，通过生物学、物理学方法、挽救实验等多方面论证ATSP1与FOXO1蛋白之间的关系，并通过对其进行稳定性修饰以提高临床应用的可行性。本研究如获成功，有望为临床治疗PCOS卵泡发育障碍提供新的候选药物。

We have found a new active peptide of ATSP1 by peptidomics techniques. It is derived from omental adipose tissue of normal women and weight loss-PCOS patients who recovered ovulating. ATSP1 is highly conserved among species and exhibits high stability which without any function report yet. Our previous study preliminary indicated that ATSP1 can promote proliferation of granulosa cells in PCOS patients in vitro and improve ovulation of PCOS model rats in vivo. FOXO1 was found to be a potential target of ATSP1 by Pull-down assay, which is a transcripition factor located in granulosa cells in ovary and plays an important regulatory role in granulosa cell function and follicle atresia. Accordingly, we propose a hypothesis that ATSP1 inhibits the function of FOXO1 and regulates biological progress of granulosa cell in PCOS. In this study we will further systematically evaluate the function of ATSP1 both in vitro and in vivo. Using FOXO1 as a mechanism clue, we will demonstrate the interaction between ATSP1 and FOXO1 through biological/physical methods and rescue experiments. We will also optimize the stability and targeting capability through modification of ATSP1 to enhance its effect in clinical application. If successful, this study may provide a new candidate therapy molecule for PCOS ovarian folliculogenesis disorders.